IGC Pharma, Inc. is a clinical-stage biotechnology company focused on advancing Alzheimer’s research. It is developing IGC-AD1, a partial CB1 receptor agonist with anti-inflammatory properties, aimed at treating agitation in patients with dementia due to Alzheimer's disease. The company conducts the CALMA trial, a multicenter Phase 2 clinical study to evaluate the safety and efficacy of IGC-AD1. Additionally, IGC Pharma utilizes artificial intelligence to enhance early detection and clinical decision support for Alzheimer’s care.
